150 related articles for article (PubMed ID: 3040850)
1. Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.
Halperin I; Rodriguez MD; Cardenal C; Casamitjana R; Martinez Osaba MJ; Lienas V; Vilardell E
J Endocrinol Invest; 1987 Jun; 10(3):277-82. PubMed ID: 3040850
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
[TBL] [Abstract][Full Text] [Related]
4. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
Schatz H; Stracke H; Hildebrandt G
Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect.
Coculescu M; Simionescu N; Oprescu M; Alessandrescu D
Endocrinologie; 1983; 21(3):157-68. PubMed ID: 6635518
[TBL] [Abstract][Full Text] [Related]
6. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
Brue T; Lancranjan I; Louvet JP; Dewailly D; Roger P; Jaquet P
Fertil Steril; 1992 Jan; 57(1):74-80. PubMed ID: 1730334
[TBL] [Abstract][Full Text] [Related]
7. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.
Lamberts SW; de Quijada M; Klijn JG
J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
[TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
[TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland.
Esiri MM; Bevan JS; Burke CW; Adams CB
J Clin Endocrinol Metab; 1986 Aug; 63(2):383-8. PubMed ID: 3722328
[TBL] [Abstract][Full Text] [Related]
12. The medical management of hormone-secreting tumors of the pituitary.
Wass JA; Besser GM
Annu Rev Med; 1983; 34():283-94. PubMed ID: 6305258
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.
Abs R; Parizel PM; Beckers A
J Endocrinol Invest; 1991 Feb; 14(2):135-8. PubMed ID: 1905737
[TBL] [Abstract][Full Text] [Related]
14. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
15. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D
Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649
[TBL] [Abstract][Full Text] [Related]
16. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
17. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
19. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size.
Oppizzi G; Liuzzi A; Chiodini P; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Tonon C
J Clin Endocrinol Metab; 1984 Jun; 58(6):988-92. PubMed ID: 6725515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
